U.S. Markets close in 31 mins

Apyx Medical Corporation (APYX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.22+0.08 (+1.56%)
As of 3:27PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.14
Bid5.21 x 900
Ask5.25 x 1000
Day's Range5.18 - 5.40
52 Week Range2.81 - 8.59
Avg. Volume131,323
Market Cap178.442M
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)-0.48
Earnings DateNov 09, 2020 - Nov 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.75
  • Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates

    Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates

    Apyx (APYX) delivered earnings and revenue surprises of 17.65% and 71.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Recap: Apyx Medical Q2 Earnings

    Shares of Apyx Medical (NASDAQ:APYX) remained unaffected after the company reported Q2 results.Quarterly Results Earnings per share were down 7.69% year over year to ($0.14), which beat the estimate of ($0.21).Revenue of $4,296,000 declined by 34.59% from the same period last year, which beat the estimate of $1,960,000.Guidance Apyx Medical hasn't issued any earnings guidance for the time being.Apyx Medical hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Aug 10, 2020View more earnings on APYXTime: 08:00 AMET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/apyx/mediaframe/39030/indexl.htmlPrice Action 52-week high: $8.59Company's 52-week low was at $2.81Price action over last quarter: Up 55.28%Company Profile Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. The company's product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives majority revenue.See more from Benzinga * P/E Ratio Insights for Apyx Medical * 17 Healthcare Stocks Moving In Tuesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Business Wire

    Apyx Medical Corporation Reports Second Quarter 2020 Financial Results

    Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its second quarter ended June 30, 2020.